Singaporeâs Temasek Holdings plans to commit up to US$ 150 million over two tranches into Redwood City, California-based Coherus BioSciences, Inc. The reason for having two tranches is essentially for hedging regulatory risk. Temasek is betting on Coherus BioSciences which is trying to take on pharmaceutical giant Amgen. Amgen has a biosimilar called Neulasta (pegfilgrastim), [âŚ]